Literature DB >> 16455631

18F-FET PET compared with 18F-FDG PET and CT in patients with head and neck cancer.

Dirk Pauleit1, Andre Zimmermann, Gabriele Stoffels, Dagmar Bauer, Jörn Risse, Michael O Flüss, Kurt Hamacher, Heinz H Coenen, Karl-Josef Langen.   

Abstract

UNLABELLED: Recent studies suggest a somewhat selective uptake of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) in cerebral gliomas and in squamous cell carcinoma (SCC) and a good distinction between tumor and inflammation. The aim of this study was to investigate the diagnostic potential of 18F-FET PET in patients with SCC of the head and neck region by comparing that tracer with 18F-FDG PET and CT.
METHODS: Twenty-one patients with suspected head and neck tumors underwent 18F-FET PET, 18F-FDG PET, and CT within 1 wk before operation. After coregistration, the images were evaluated by 3 independent observers and an ROC analysis was performed, with the histopathologic result used as a reference. Furthermore, the maximum standardized uptake values (SUVs) in the lesions were determined.
RESULTS: In 18 of 21 patients, histologic examination revealed SCC, and in 2 of these patients, a second SCC tumor was found at a different anatomic site. In 3 of 21 patients, inflammatory tissue and no tumor were identified. Eighteen of 20 SCC tumors were positive for both 18F-FDG uptake and 18F-FET uptake, one 0.3-cm SCC tumor was detected neither with 18F-FDG PET nor with 18F-FET PET, and one 0.7-cm SCC tumor in a 4.3-cm ulcer was overestimated as a 4-cm tumor on 18F-FDG PET and missed on 18F-FET PET. Inflammatory tissue was positive for 18F-FDG uptake (SUV, 3.7-4.7) but negative for 18F-FET uptake (SUV, 1.3-1.6). The SUVs of 18F-FDG in SCC were significantly higher (13.0 +/- 9.3) than those of 18F-FET (4.4 +/- 2.2). The ROC analysis showed significantly superior detection of SCC with (18)F-FET PET or 18F-FDG PET than with CT. No significant difference (P = 0.71) was found between 18F-FDG PET and 18F-FET PET. The sensitivity of 18F-FDG PET was 93%, specificity was 79%, and accuracy was 83%. 18F-FET PET yielded a lower sensitivity of 75% but a substantially higher specificity of 95% (accuracy, 90%).
CONCLUSION: 18F-FET may not replace 18F-FDG in the PET diagnostics of head and neck cancer but may be a helpful additional tool in selected patients, because 18F-FET PET might better differentiate tumor tissue from inflammatory tissue. The sensitivity of 18F-FET PET in SCC, however, was inferior to that of 18F-FDG PET because of lower SUVs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16455631

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

1.  From anatomical to biological target volumes: the role of PET in radiation treatment planning.

Authors:  D A X Schinagl; J H A M Kaanders; W J G Oyen
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

2.  Selecting the optimal image segmentation strategy in the era of multitracer multimodality imaging: a critical step for image-guided radiation therapy.

Authors:  Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-08       Impact factor: 9.236

3.  Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients.

Authors:  Ken Herrmann; Johannes Czernin; Timothy Cloughesy; Albert Lai; Kelsey L Pomykala; Matthias R Benz; Andreas K Buck; Michael E Phelps; Wei Chen
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

4.  Diagnostic usefulness of ¹⁸F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma.

Authors:  Aiko Nobusawa; Mai Kim; Kyoichi Kaira; Go Miyashita; Akihide Negishi; Noboru Oriuchi; Tetsuya Higuchi; Yoshito Tsushima; Yoshikatsu Kanai; Satoshi Yokoo; Tetsunari Oyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-06-26       Impact factor: 9.236

5.  Uptake and tracer kinetics of O-(2-(18)F-fluoroethyl)-L-tyrosine in meningiomas: preliminary results.

Authors:  Jan F Cornelius; Gabriele Stoffels; Christian Filß; Norbert Galldiks; Philipp Slotty; Marcel Kamp; Mustafa el Khatib; Daniel Hänggi; Michael Sabel; Jörg Felsberg; Hans Jakob Steiger; Heinz H Coenen; Nadim J Shah; Karl-Josef Langen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-21       Impact factor: 9.236

6.  18F-FET PET/CT in advanced head and neck squamous cell carcinoma: an intra-individual comparison with 18F-FDG PET/CT.

Authors:  Stephan Kurt Haerle; Dorothee R Fischer; Daniel T Schmid; Nader Ahmad; Gerhard F Huber; Alfred Buck
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

7.  TNM staging with FDG-PET/CT in patients with primary head and neck cancer.

Authors:  Patrick Veit-Haibach; Christopher Luczak; Isabel Wanke; Markus Fischer; Thomas Egelhof; Thomas Beyer; Gerlinde Dahmen; Andreas Bockisch; Sandra Rosenbaum; Gerald Antoch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-24       Impact factor: 9.236

8.  Prospective comparison of FDG and FET PET/CT in patients with head and neck squamous cell carcinoma.

Authors:  S Balogova; S Périé; K Kerrou; D Grahek; F Montravers; B Angelard; B Susini; P El Chater; J Lacau St Guily; J N Talbot
Journal:  Mol Imaging Biol       Date:  2008-07-31       Impact factor: 3.488

Review 9.  Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

Authors:  Mark P S Dunphy; Jason S Lewis
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

10.  Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer.

Authors:  Akram Al-Ibraheem; Andreas Buck; Bernd Joachim Krause; Klemens Scheidhauer; Markus Schwaiger
Journal:  J Oncol       Date:  2009-08-20       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.